Click here to read part 1 of this series
The FY2027 U.S. Health and Human Services (HHS) budget proposal and the U.S. Food and Drug Administration’s (FDA) evolving priorities point to a more complex and, in some cases, less predictable environment for the rare disease ecosystem. Proposed reductions in early-stage research funding are expected to tighten the pipeline of new therapies, while at the same time the FDA is advancing efforts to accelerate development and strengthen the U.S. as a hub for clinical activity.
Recent regulatory decisions add another layer, reinforcing that while timelines may be compressed, expectations around evidence, clinical design, and overall rigor remain high.
As these dynamics continue to unfold, how companies engage in the conversation will matter just as much as what they say, and how well those messages reflect the realities of development, investment, and regulatory strategy.
Areas to prioritize
- Connect early research to patient impact: There is an opportunity to more clearly link early-stage research funding to real-world patient outcomes. For rare disease companies, where progress is closely tied to sustained scientific investment, this connection is particularly important to reinforce.
- Be ready to talk about development strategy: Questions around where and how programs are being developed are likely to become more frequent. This may include trial location planning, timing of clinical milestones, and how evolving FDA pathways are influencing decision-making, even when those topics are not the primary focus of a discussion.
- Address U.S. investment and development footprint: The FDA’s proposals signal a growing emphasis on bringing development activity into the U.S. Companies should be prepared to articulate how they are approaching investment, clinical strategy, and long-term presence in that context.
- Reflect the full environment without overreaching: There is still uncertainty around what will ultimately be enacted. Effective messaging will acknowledge both the challenges and the opportunities, staying grounded in what is known while avoiding unnecessary speculation.
- Elevate the rare disease lens: These policy shifts do not affect all therapeutic areas equally. Rare disease companies should be prepared to clearly articulate how changes to research funding, regulatory expectations, and development incentives uniquely impact their space.
Looking ahead
As policy discussions continue and priorities evolve, the environment for rare disease companies is likely to remain fluid. The intersection of funding constraints, regulatory acceleration, and heightened scrutiny is shaping not only how therapies are developed, but also how companies are expected to communicate about that work.
Our role is to help clients navigate that complexity in a way that is both credible and grounded in reality, connecting scientific strategy, business decisions, and patient impact into a clear and consistent narrative. Clear, consistent messaging that reflects both the realities of rare disease development and the broader system dynamics shaping the environment will be increasingly important.
